Experimental injections target liver damage in rare genetic disorder
NCT ID NCT02900183
Summary
This study aimed to test whether multiple doses of an experimental drug called ARC-AAT could safely reduce the buildup of a harmful protein in the livers of adults with Alpha-1 Antitrypsin Deficiency. Participants would have received seven intravenous injections and undergone two liver biopsies to measure the drug's effect. The trial was withdrawn before any patients were enrolled.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALPHA 1-ANTITRYPSIN DEFICIENCY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Toronto, Ontario, M5T3A9, Canada
-
Research Site 2
Dublin, Ireland
-
Research Site 3
Pavia, 27100, Italy
-
Research Site 4
Malmo, SE-205 02, Sweden
Conditions
Explore the condition pages connected to this study.